Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Has Consensus Price Target of $13.20 According to Analysts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has earned a consensus rating of “Hold” from the seven brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $13.20.

Several research analysts have commented on XERS shares. Barclays lifted their price target on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 6th. Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Leerink Partners upped their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, September 10th. Finally, Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th.

Insider Buying and Selling

In other Xeris Biopharma news, insider Kevin McCulloch sold 25,000 shares of the company’s stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. Following the completion of the sale, the insider directly owned 1,614,208 shares in the company, valued at $16,142,080. This represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.41, for a total transaction of $47,050.00. Following the sale, the insider owned 1,351,053 shares of the company’s stock, valued at approximately $12,713,408.73. The trade was a 0.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 134,998 shares of company stock worth $1,202,666 in the last 90 days. 4.35% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Allworth Financial LP grew its position in Xeris Biopharma by 86.4% during the 2nd quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock worth $34,000 after acquiring an additional 2,000 shares during the last quarter. AlphaCentric Advisors LLC increased its stake in Xeris Biopharma by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock worth $266,000 after purchasing an additional 2,494 shares during the period. GK Wealth Management LLC purchased a new position in Xeris Biopharma in the 3rd quarter worth approximately $32,000. KBC Group NV purchased a new position in Xeris Biopharma in the 1st quarter worth approximately $27,000. Finally, Royal Bank of Canada increased its stake in Xeris Biopharma by 12.9% in the 1st quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock worth $253,000 after purchasing an additional 4,974 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Stock Performance

Shares of NASDAQ XERS opened at $10.31 on Friday. The stock’s 50-day moving average is $8.88 and its 200 day moving average is $7.65. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of -93.73 and a beta of 0.53. Xeris Biopharma has a 1-year low of $5.25 and a 1-year high of $11.33. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The firm had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. On average, sell-side analysts anticipate that Xeris Biopharma will post 0.07 EPS for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome.